The Federal Circuit reversed the District of Delaware’s decision to invalidate Orexo’s opioid treatment patent as obvious because obviousness was not proved by clear and convincing evidence. Specifically, the Court pointed to the absence of a teaching in the prior art that citric acid could serve as a carrier particle for the drug agonist. The Court also noted that the lower court improperly discounted evidence of objective indicia of nonobviousness.
The post Federal Circuit Reverses, Finds Opioid Addiction Treatment Patent Nonobvious appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Massie Tells House IP Subcommittee Witnesses He’s ‘Appalled’ By Proposals to Rein in ITC’s Patent Powers
- CAFC Invalidates Remaining Claim on Data Transmission Patent, Remands Substitute Claims for Collateral Estoppel Determination
- NIH Intramural Licensing Guidelines Hit the Wrong Note at the Wrong Time
- Other Barks & Bites for Friday, July 19: UPC Issues First-Ever Patent Revocation; Meta Announces Latest AI Model Won’t be Released in EU Due to Regulatory Concerns; and CAFC Dismisses PTAB Appeal as Moot Due to Prior District Court Invalidation
- Federal Circuit Affirms Ineligibility of Background Check Patent Claims